Skip To Main Content
Claudia Bardoni on Muck Rack

Claudia Bardoni

As seen in: MDPI, EMJ- European Medical Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Claudia

Contact Claudia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

From cytology to systems pathology: Decoding the molecular heterogeneity of resectable non-small-cell lung cancer

|
By Claudia Bardoni, Monica Casiraghi, Luca Bertolaccini
| cytojournal.com
Translate this page into: doi: 10.25259/Cytojournal_190_2025 , , , , 1Department of Thoracic Surgery, IEO-European Institute of Oncology, Milan, Italy, 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Dear Editor, Non-small-cell lung cancer (NSCLC) represents 85% of lung malignancies and the predominant cause of cancer deaths globally.
Open in Who Shared Issue with article?

Precision Strikes: Personalising Potentially Surgically Resectable Stage IIIA Lung Cancer Treatment with Targeted and Immune Therapies

|
By Luca Bertolaccini, Monica Casiraghi, Antonio Mazzella, Claudia Bardoni
| EMJ- European Medical Journal Verified
INTRODUCTION The treatment landscape for potentially surgically resectable Stage IIIA non-small cell lung cancer (NSCLC), particularly for adenocarcinoma and squamous carcinoma, has evolved significantly in recent years. Up to now, in patients diagnosed with Stage IIIA NSCLC, the standard approach typically began with neoadjuvant therapies followed by surgical resection, which is considered the cornerstone of treatment.
Open in Who Shared Issue with article?

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

|
By Luca Bertolaccini, Monica Casiraghi, Claudia Bardoni, Cristina Diotti
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 5 articles